kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Human Oncostatin M (OSM) Protein, Avitag™,His Tag, 25µg  

Recombinant Biotinylated Human Oncostatin M (OSM) Protein, Avitag™,His Tag, 25µg

Recombinant Biotinylated Human Oncostatin M (OSM) Protein, AA Ala 26 - Arg 221, expressed from human 293 cells (HEK293), Avitag™,His Tag

Synonym: Recombinant Human Protein, OSM, MGC20461, Oncostatin M

More details


Availability: within 7 days

455,00 €

Oncostatin M is also known as OSM, is a glycoprotein belonging to the interleukin-6 family of cytokines that has functions mainly in cell growth. Of these cytokines it most closely resembles leukemia inhibitory factor (LIF) in both structure and function. However, it is as yet poorly defined and is proving important in liver development, haematopoeisis, inflammation and possibly CNS development. It is also associated with bone formation and destruction. OSM signals through cell surface receptors that contain the protein gp130. The type I receptor is composed of gp130 and LIFR, the type II receptor is composed of gp130 and OSMR. Oncostatin M (OSM) was previoustly identified by its ability to inhibit the growth of cells from melanoma and other solid tumors. It also has been reported that OSM, like LIF, IL-6 and G-CSF, has the ability to inhibit the proliferation of murine M1 myeloid leukemic cells and can induce their differentiation into macrophage-like cells. The human form of OSM is insensitive between pH2 and 11 and resistant to heating for one hour at 56 degree but is not stable at 90 degrees. The three dimensional structure of human OSM has been solved to atomic resolution, confirming the predicted long chain four helix bundle topology. Comparing this structure with the known structures of other known LC cytokines shows it to be most closely related to LIF.

Recombinant Biotinylated Human Oncostatin M, Avitag,His Tag (OSM-H82Q8) is expressed from human 293 cells (HEK293). It contains AA Ala 26 - Arg 221 (Accession # P13725-1).
Predicted N-terminus: Gly

Molecular Characterization
This protein carries an Avi tag at the N-terminus, followed by a polyhistidine tag.
The protein has a calculated MW of 25.7 kDa. The protein migrates as 30-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Less than 1.0 EU per μg  by the LAL method.

>90% as determined by SDS-PAGE.

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Rescue IVM of Denuded GV- and MI-Stage Oocytes of Premenopausal Rats with Oncostatin M, Insulin-like Growth Factor I, and Growth Hormone"
Akdemir, Donmez Cakil, Selam et al
Life (Basel) (2022) 12 (8)
(2) Injectable hydrogel with dual-sensitive behavior for targeted delivery of oncostatin M to improve cardiac restoration after myocardial infarction"
Jiang, Niu, Lin et al
J Mater Chem B (2022)
(3) "Oncostatin M attenuates tumor necrosis factor-α-induced synthesis of macrophage-colony stimulating factor via suppression of Akt in osteoblasts"
Hioki, Kuroyanagi, Matsushima-Nishiwaki et al
Connect Tissue Res (2022)
Showing 1-3 of 2047 papers.